Humacyte Inc [NASDAQ: HUMA] gained 18.70% on the last trading session, reaching $2.73 price per share at the time.
Humacyte Inc represents 155.12 million in outstanding shares, while the company has a total market value of $423.47 million with the latest information. HUMA stock price has been found in the range of $2.33 to $2.839.
If compared to the average trading volume of 3.91M shares, HUMA reached a trading volume of 11996703 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Humacyte Inc [HUMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HUMA shares is $9.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HUMA stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Humacyte Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 14, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $12 to $15. The new note on the price target was released on December 20, 2024, representing the official price target for Humacyte Inc stock. Previously, the target price had yet another raise to $6, while H.C. Wainwright analysts kept a Buy rating on HUMA stock. On August 14, 2023, analysts increased their price target for HUMA shares from 2.75 to 3.50.
The Price to Book ratio for the last quarter was 11.75, with the Price to Cash per share for the same quarter was set at 0.41.
Trading performance analysis for HUMA stock
Humacyte Inc [HUMA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.23. With this latest performance, HUMA shares gained by 23.53% in over the last four-week period, additionally sinking by -40.13% over the last 6 months – not to mention a drop of -45.94% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HUMA stock in for the last two-week period is set at 62.46, with the RSI for the last a single of trading hit 0.22, and the three-weeks RSI is set at 0.21 for Humacyte Inc [HUMA]. The present Moving Average for the last 50 days of trading for this stock 2.36, while it was recorded at 2.42 for the last single week of trading, and 3.44 for the last 200 days.
Humacyte Inc [HUMA]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Humacyte Inc [HUMA] shares currently have an operating margin of -21470.79% and a Gross Margin at -1335.59%. Humacyte Inc’s Net Margin is presently recorded at -15481.62%.
Humacyte Inc (HUMA) Capital Structure & Debt Analysis
According to recent financial data for Humacyte Inc. ( HUMA), the Return on Equity (ROE) stands at -257.38%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -49.40%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Humacyte Inc’s Return on Invested Capital (ROIC) is -70.48%, showcasing its effectiveness in deploying capital for earnings.
Humacyte Inc (HUMA) Efficiency & Liquidity Metrics
Based on Humacyte Inc’s (HUMA) latest financial statements, the Debt-to-Equity Ratio is 2.28%, indicating its reliance on debt financing relative to shareholder equity.
Humacyte Inc (HUMA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Humacyte Inc. (HUMA) effectively leverages its workforce, generating an average of -$363818.18 per employee. The company’s liquidity position is robust, with a Current Ratio of 3.68% and a Quick Ratio of 3.28%, indicating strong ability to cover short-term liabilities.
An analysis of Institutional ownership at Humacyte Inc [HUMA]
There are presently around $40.15%, or 50.29% of HUMA stock, in the hands of institutional investors. The top three institutional holders of HUMA stocks are: BLACKROCK INC. with ownership of 7.14 million shares, which is approximately 5.9912%. VANGUARD GROUP INC, holding 4.73 million shares of the stock with an approximate value of $$22.7 million in HUMA stocks shares; and VANGUARD GROUP INC, currently with $$13.77 million in HUMA stock with ownership which is approximately 2.4071%.
